배영철 CBO 인터뷰, 아미노산 서열 분석으로 혁신신약 후보물질 발굴, 각 제약사에 맞는 플랫폼 판매도 계획
Read More
“AI drug discovery companies should have technical skills and mid-to-long-term business model.”
One of the most significant business models for AI drug development companies is collaborating with global companies..
Read More
Deargen-NeogenTC, Announced a research collaboration on developing an AI platform for cancer immunotherapy.
Deargen starts a research collaboration with NeogenTC to develop a TCR-T treatment prediction platform using Deargen’s sequence-based AI technology.
Read More
디어젠-네오젠TC, AI면역세포 치료제 플랫폼 공동연구
디어젠이 네오젠TC와 함께 시퀀스기반 AI기술을 활용한 TCR-T치료제 예측플랫폼 개발을 시작했습니다.
Read More
[Interview] “Dongtan RnD Center, iDear Center, will be an outpost of anti-cancer drugs”
The first interview article on Kilsoo Kang, CEO of Deargen, after he successfully secured the SeriesB funding round.
Read More
“동탄연구소 아이디어센터, 항암신약 개발 전초기지로”
강길수 디어젠 대표이사, 시리즈B 완료 이후 첫 인터뷰 기사 공개
Read More
Deargen, Accepted its research paper at AAAI Conference…“Introducing a new model for enhancement of estimation of certainty in new drug candidates.”
Deargen presented a new AI technology on ‘enhanced model on estimating certainty in new drug candidates.’
Read More
디어젠, 인공지능 학회 AAAI 논문 채택…“약물후보물질 예측 정확도 향상 모델 공개”
디어젠, AAAI 2022에서 ‘약물후보물질 예측 정확도 향상 모델’에 대한 신기술 개발 성과 공개
Read More
Sequence Based, AI-Driven Drug Discovery Company, Deargen Raises US$17 Million in SeriesB Financing Round to Accelerate In-House Pipeline
Will establish a 2,600m2 AI convergence new drug development center (iDear Center) and accelerate internal new drug development
Read More
[보도자료] 디어젠(주), 시리즈B 200억 유치… “800평 규모 인공지능 융합 신약개발연구소 신설”
기존 투자자 하나벤처스, 티에스인베스트먼트 외 신규 투자자 엔베스터, 더웰스인베스트먼트, 산업은행 등 참여
Read More